http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2311909-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_105f5a3002f31ca7e28956e60a952c80
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
filingDate 2005-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c42c4150f23fc259219446d27f638aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31f310f6dc8096df05a83ae49719df05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_861d0c5c5302e8bb81b5c7201bf1a0e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b195c1f21a06bdbb9817a849ddedc0af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44909fe2b860a075e4614c7307b77ea2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d34defc80bf88d11bcc30b612a203a5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22bee6f561c6fec6e5494ce99a14a5ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d71ec3dd3941e39655c348860db6507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9bc78e359e38d2eb52f1e91d4fbf138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6a0ffb3cab460947b44cd2809f15fdb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e25c9daf9e89918a0609fa086542a68f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bae3a44932d7f0b9d05cb09196af21f0
publicationDate 2007-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2311909-C2
titleOfInvention Method for treating rectal cancer
abstract FIELD: medicine, oncology. n SUBSTANCE: in pre-surgical period in the 1 st , 3d, 5 th d of a 5-d-long irradiation course it is necessary to carry out a seance of distance gamma-therapy at single focal dosage (SFD) being 5 Gy at the background of a double intake of capecytabin at its daily dosage of 1.5 g/sq. m body surface. In the 2 nd and 4 th d at the background of a double intake of capecytabin at the same dosage, one should intrarectally introduce metronidasol at the rate of 10 g/sq. m body surface and after a 6-h-long exposure one should carry out a seance of distance gamma-therapy at SFD being 5 Gy. Moreover, metronidasol should be introduced as a composite mixture at the following ratios of the ingredients, weight%: metronidasol 12-22; sodium alginate 4-6; dimethyl sulfoxide 2; distilled water - up to 100. The innovation provides taking antilogarithms of the effect of radiomodifiers of different direction at the background of radiation therapy and, thus, the absence of locoregional relapses for the period of 2 yr, the decrease in the onset of distant metastases and the increased frequency in achieving radial pathomorphosis of degree III in the tumor. n EFFECT: higher efficiency of therapy. n 1 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2477641-C1
priorityDate 2005-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538066
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504160
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450984220
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5102882
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4173
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID679
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590338

Total number of triples: 36.